MedPage Today -- CHICAGO -- Positive early phase results could put a novel inhibitor of “sonic hedgehog” signaling in line to be the first targeted agent in the most common type of childhood brain tumor.
MedPage Today -- CHICAGO -- Positive early phase results could put a novel inhibitor of “sonic hedgehog” signaling in line to be the first targeted agent in the most common type of childhood brain tumor.
